Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 44, Issue 9

Issues

Lipid peroxidation and homocysteine levels in Behçet's disease

A. Görkem Mungan / Murat Can / Serefden Açikgöz / Emel Eştürk / Cevdet Altinyazar
Published Online: 2006-09-08 | DOI: https://doi.org/10.1515/CCLM.2006.191

Abstract

Background: The aim of this study was to investigate serum paraoxonase (PON1) activity in relation to homocysteine, malondialdehyde (MDA) and lipid parameters in active and inactive Behçet's disease (BD).

Methods: A total of 46 consecutive BD patients and 25 healthy control subjects were included in the present study.

Results: Serum PON1 activity in both active and inactive BD was significantly lower compared with healthy subjects (p<0.05). When compared to the control group, serum MDA levels were significantly higher in both active and inactive BD (p<0.05). Serum C-reactive protein (CRP) and homocysteine concentrations were significantly higher in active BD than those in inactive BD and control subjects (p<0.05). In addition, there was significant negative correlation between serum PON1 and MDA levels (r=−0.697, p<0.05) and serum PON1 activity was also negatively correlated with homocysteine levels (r=−0.428, p<0.05) in BD patients.

Conclusions: Decreased PON1 could explain the increased lipid peroxidation and oxidative stress observed in BD. Also, according to our results, we suggest that homocysteine may contribute to decreased serum PON1 activity.

Clin Chem Lab Med 2006;44:1115–8.

Keywords: Behçet's disease; homocysteine; lipid peroxidation; paraoxonase

References

  • 1.

    Behçet H. Über residivierende Aphthose, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937; 105:1152–7.Google Scholar

  • 2.

    Ghate JV, Jorizzo JL. Behçet's disease, and complex aphthosis. J Am Acad Dermatol 1999; 40:1–18.CrossrefGoogle Scholar

  • 3.

    Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999; 341:1284–91.Web of ScienceGoogle Scholar

  • 4.

    Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354:407–13.Google Scholar

  • 5.

    Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001; 81:645–72.CrossrefGoogle Scholar

  • 6.

    Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenbalt M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998; 18:1617–24.CrossrefGoogle Scholar

  • 7.

    Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M. Auto-oxidative damage in Behcet's disease – endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982; 49:247–55.Google Scholar

  • 8.

    Takeno M, Kariyone A, Yamashita N. Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA B51 transgenic mice. Arthritis Rheum 1995; 38:426–33.CrossrefGoogle Scholar

  • 9.

    Kose K, Yazici C, Ascıoglu O. The evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behcet's disease. Clin Biochem 2001; 34:125–9.CrossrefGoogle Scholar

  • 10.

    Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome. J Am Coll Cardiol 2001; 37:517–20.CrossrefGoogle Scholar

  • 11.

    Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005; 50:297–350.CrossrefGoogle Scholar

  • 12.

    Ozdemir R, Barutcu I, Sezgin AT, Acikgoz N, Ermis N, Metin Esen A, et al. Vascular endothelial function and plasma homocysteine levels in Behcet's disease. Am J Cardiol 2004; 94:522–5.CrossrefGoogle Scholar

  • 13.

    Karakucuk S, Baskol G, Oner AO, Baskol M, Mirza E, Ustdal M. Serum paraoxonase activity is decreased in the active stage of Behcet's disease. Br J Ophthalmol 2004; 88:1256–8.CrossrefGoogle Scholar

  • 14.

    International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078–80.Google Scholar

  • 15.

    Hunter MI, Nlemadim BC, Davidson DI. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 1985; 10:1645–52.CrossrefGoogle Scholar

  • 16.

    Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19:100–6.Google Scholar

  • 17.

    Erkilic K, Evereklioglu C, Cekmen M, Ozkiriş A, Duygulu F, Dogan H. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behcet's disease: original contributions/clinical and laboratory investigations. Mediators Inflamm 2003; 12:107–16.CrossrefGoogle Scholar

  • 18.

    Kokcam I, Naziroglu M. Effects of vitamin E supplementation on blood antioxidants levels in patients with Behcet's disease. Clin Biochem 2002; 35:633–9.CrossrefGoogle Scholar

  • 19.

    Kose K, Yazici C, Cambay N, Ascioglu O, Dogan P. Lipid peroxidation and erythrocyte antioxidant enzymes in patients with Behcet's disease. Tohoku J Exp Med 2002; 197:9–16.Google Scholar

  • 20.

    Geisel J, Hubner U, Bodis M, Schorr H, Knapp JP, Obeid R, et al. The role of genetic factors in the development of hyperhomocysteinemia. Clin Chem Lab Med 2003; 41:1427–34.CrossrefGoogle Scholar

  • 21.

    Draper H, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990; 186:421–31.Google Scholar

  • 22.

    Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:473–80.CrossrefGoogle Scholar

  • 23.

    Sanvanich P, Mackness B, Gaskell SJ, Durrington P, Mackness M. The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein. Biochem Biophys Res Commun 2003; 300:501–6.Google Scholar

  • 24.

    Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffmann A, et al. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase like activities. Circulation 2000; 101:2510–7.CrossrefGoogle Scholar

  • 25.

    Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001; 81:645–72.CrossrefGoogle Scholar

  • 26.

    Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, et al. Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272:17012–7.Google Scholar

  • 27.

    Ates A, Aydıntug O, Olmez U, Duzgun N, Duman M. Serum homocysteine level is higher in Behcet's disease with vascular involvement. Rheumatol Int 2005; 25:42–4.CrossrefGoogle Scholar

  • 28.

    Canataroglu A, Tanriverdi K, Inal T, Seydaoglu G, Arslan D, Ozbek S, et al. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behcet's disease. Rheumatol Int 2003; 23:236–40.CrossrefGoogle Scholar

  • 29.

    Evereklioglu C, Cumurcu T, Türköz Y, Özerol E, Sahin K, Doganay S. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br J Ophthalmol 2002; 86:653–7.CrossrefGoogle Scholar

  • 30.

    Blacher J, Benetos A, Kirzin JM, Malmejac A, Guize L, Safar ME. Relation of plasma total homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002; 90:591–5.CrossrefGoogle Scholar

  • 31.

    Stuart MJ. Platelet malonyldialdehyde formation: an indicator of platelet hyperfunction. Thromb Haemost 1979; 42:649–54.Google Scholar

  • 32.

    Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999; 13:2277–83.Google Scholar

  • 33.

    Jakubowski H. Homocysteine thiolactone and S-nitrosohomocysteine mediate incorporation of homocysteine into protein in humans. Clin Chem Lab Med 2003; 41:1462–6.CrossrefGoogle Scholar

  • 34.

    Janel N, Robert K, Chabert C, Ledru A, Gouedard C, Barouki R, et al. Mouse liver paraoxonase-1 gene expression is downregulated in hyperhomocysteinemia. Thromb Haemost 2004; 92:221–2.Google Scholar

About the article

Corresponding author: Murat Can, Karaelmas University, Faculty of Medicine, Department of Biochemistry, Zonguldak, Turkey Phone: +90-372-2610169, Fax: +90-372-2610155,


Received: 2006-02-06

Accepted: 2006-05-31

Published Online: 2006-09-08

Published in Print: 2006-09-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 44, Issue 9, Pages 1115–1118, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2006.191.

Export Citation

©2006 by Walter de Gruyter Berlin New York.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
P.E. Lazzerini, P.L. Capecchi, E. Selvi, S. Lorenzini, S. Bisogno, M. Galeazzi, and F. Laghi Pasini
Lupus, 2007, Volume 16, Number 11, Page 852
[2]
Ahmet Demirkol, Murat Uludag, Neslihan Soran, Nurten Aksoy, Kerem Gun, Serap Incebıyık, Ismahan Gurgen, Mehmet Vural, Yasşar Altun, and Fatma Nur Kesiktas
Redox Report, 2012, Volume 17, Number 6, Page 234
[3]
Ahmed Allam, Hatem Ammar, and Abdullah Radwan
The Egyptian Rheumatologist, 2014, Volume 36, Number 1, Page 29
[4]
Nadia Koubaa, Sonia Hammami, Amel Nakbi, Khaldoun Ben Hamda, Sylvia Mahjoub, Testsuya Kosaka, and Mohamed Hammami
Clinical Chemical Laboratory Medicine, 2008, Volume 46, Number 2
[5]
Müzeyyen Gönül, Ülker Gül, Cumhur Kılınç, Seray Külcü Çakmak, Seçil Soylu, and Arzu Kılıç
Clinical Rheumatology, 2009, Volume 28, Number 10, Page 1153
[6]
Mehmet Karakoc, Ozlem Altindag, Huseyin Keles, Neslihan Soran, and Sahabettin Selek
Rheumatology International, 2007, Volume 27, Number 12, Page 1131

Comments (0)

Please log in or register to comment.
Log in